179 related articles for article (PubMed ID: 30144155)
1. Immunological dysfunction in chronic arsenic exposure: From subclinical condition to skin cancer.
Yu S; Liao WT; Lee CH; Chai CY; Yu CL; Yu HS
J Dermatol; 2018 Nov; 45(11):1271-1277. PubMed ID: 30144155
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of arsenic on cutaneous and systemic immunity: focusing on CD4+ cell apoptosis in patients with arsenic-induced Bowen's disease.
Liao WT; Yu CL; Lan CC; Lee CH; Chang CH; Chang LW; You HL; Yu HS
Carcinogenesis; 2009 Jun; 30(6):1064-72. PubMed ID: 19376847
[TBL] [Abstract][Full Text] [Related]
3. Arsenic carcinogenesis in the skin.
Yu HS; Liao WT; Chai CY
J Biomed Sci; 2006 Sep; 13(5):657-66. PubMed ID: 16807664
[TBL] [Abstract][Full Text] [Related]
4. Aberrant immune responses in arsenical skin cancers.
Lee CH; Liao WT; Yu HS
Kaohsiung J Med Sci; 2011 Sep; 27(9):396-401. PubMed ID: 21914527
[TBL] [Abstract][Full Text] [Related]
5. Arsenic-Induced Carcinogenesis and Immune Dysregulation.
Huang HW; Lee CH; Yu HS
Int J Environ Res Public Health; 2019 Aug; 16(15):. PubMed ID: 31374811
[TBL] [Abstract][Full Text] [Related]
6. Quantitative and morphological changes of Langerhans cells in Bowen's disease from patients with chronic arsenicism.
Wang BJ; Lee YY; Mak CP; Kao HF; Hsu ML; Hsien JR
J Formos Med Assoc; 1991 Nov; 90(11):1093-8. PubMed ID: 1687057
[TBL] [Abstract][Full Text] [Related]
7. Arsenic mobilizes Langerhans cell migration and induces Th1 response in epicutaneous protein sensitization via CCL21: a plausible cause of decreased Langerhans cells in arsenic-induced intraepithelial carcinoma.
Lee CH; Hong CH; Yu CL; Wang LF; Clausen BE; Liao WT; Huang SK; Chen GS; Yu HS
Biochem Pharmacol; 2012 May; 83(9):1290-9. PubMed ID: 22321510
[TBL] [Abstract][Full Text] [Related]
8. Merkel cell carcinoma and multiple Bowen's disease: incidental association or possible relationship to inorganic arsenic exposure?
Ohnishi Y; Murakami S; Ohtsuka H; Miyauchi S; Shinmori H; Hashimoto K
J Dermatol; 1997 May; 24(5):310-6. PubMed ID: 9198320
[TBL] [Abstract][Full Text] [Related]
9. The role of oxidative DNA damage in human arsenic carcinogenesis: detection of 8-hydroxy-2'-deoxyguanosine in arsenic-related Bowen's disease.
Matsui M; Nishigori C; Toyokuni S; Takada J; Akaboshi M; Ishikawa M; Imamura S; Miyachi Y
J Invest Dermatol; 1999 Jul; 113(1):26-31. PubMed ID: 10417614
[TBL] [Abstract][Full Text] [Related]
10. Alterations of skin-associated lymphoid tissue in the carcinogenesis of arsenical skin cancer.
Yu HS; Chen GS; Sheu HM; Kao JS; Chang KL; Yu CL
Proc Natl Sci Counc Repub China B; 1992 Jan; 16(1):17-22. PubMed ID: 1385879
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous and induced sister chromatid exchanges and delayed cell proliferation in peripheral lymphocytes of Bowen's disease patients and matched controls of arseniasis-hyperendemic villages in Taiwan.
Hsu YH; Li SY; Chiou HY; Yeh PM; Liou JC; Hsueh YM; Chang SH; Chen CJ
Mutat Res; 1997 Jun; 386(3):241-51. PubMed ID: 9219562
[TBL] [Abstract][Full Text] [Related]
12. Arsenic-induced keratoses and Bowen's disease.
Watson K; Creamer D
Clin Exp Dermatol; 2004 Jan; 29(1):46-8. PubMed ID: 14723721
[TBL] [Abstract][Full Text] [Related]
13. A case of Bowen's disease and small-cell lung carcinoma: long-term consequences of chronic arsenic exposure in Chinese traditional medicine.
Lee L; Bebb G
Environ Health Perspect; 2005 Feb; 113(2):207-10. PubMed ID: 15687059
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous manifestations of chronic arsenicism: review of seventeen cases.
Wong SS; Tan KC; Goh CL
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):179-85. PubMed ID: 9486671
[TBL] [Abstract][Full Text] [Related]
15. Ureteral tumor with multiple Bowen's disease forty-two years after exposure to arsenic.
Koh E; Kondoh N; Kaihara H; Fujioka H; Kitamura K
Eur Urol; 1989; 16(5):398-400. PubMed ID: 2776813
[TBL] [Abstract][Full Text] [Related]
16. Bowen's disease of the plantar arch.
Allen RB; Richardson DR; Futrell JW
Cutis; 1979 Jun; 23(6):805-7. PubMed ID: 467101
[TBL] [Abstract][Full Text] [Related]
17. Role of mitochondria, ROS, and DNA damage in arsenic induced carcinogenesis.
Lee CH; Yu HS
Front Biosci (Schol Ed); 2016 Jun; 8(2):312-20. PubMed ID: 27100709
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 promoter -56 and -54bp CpG un-methylation predicts invasive progression in arsenic-induced Bowen's disease.
Liao WT; You HL; Chai CY; Lee CH; Lan CE; Chang SJ; Yu CL; Yu HS
J Dermatol Sci; 2018 Feb; 89(2):191-197. PubMed ID: 29103775
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive and cytotoxic cells in invasive vs. non-invasive Bowen's disease.
Furudate S; Fujimura T; Kambayashi Y; Haga T; Hashimoto A; Aiba S
Acta Derm Venereol; 2014 May; 94(3):337-9. PubMed ID: 24158393
[No Abstract] [Full Text] [Related]
20. [Bowen's disease with multiple lesions caused by chronic arsenic poisoning].
Giménez H; Agurruza JM; Martínez G; Grasa MP; Carapeto FJ
Actas Dermosifiliogr; 1980; 71(9-10):337-42. PubMed ID: 7223522
[No Abstract] [Full Text] [Related]
[Next] [New Search]
